Binding and functional comparisons of two types of tumor necrosis factor antagonists

Journal of Pharmacology and Experimental Therapeutics

Volumn 301, Issue 2, 2002, Pages 418-426

  Scallon, Bernie ^a   Cai, Ann ^a   Solowski, Nancy ^a   Rosenberg, Amy ^a   Song, Xiao Yu ^a   Shealy, David ^a   Wagner, Carrie ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; IODINE 125; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CELL KINETICS; COMPLEX FORMATION; CROHN DISEASE; DRUG BINDING; DRUG EFFICACY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BINDING SITES; CELLS, CULTURED; HUMANS; IMMUNOGLOBULIN G; MICE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036229932     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.301.2.418     Document Type: Article

References (39)

1. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation
2. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
3. The minor necrosis factor ligand and receptor families
4. Identification of an inducible endothelial-leukocyte adhesion molecule
5. Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
6. TNF receptor fusion proteins are effective inhibitors of TNF-inediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells
7. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial
8. Oligomeric tumour necrosis factor alpha slowly converts into inactive forms at bioactive levels
9. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis
10. Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of grain-negative sepsis
11. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein
12. Interleukin-8, interleukin-10, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 expression levels are higher in synovial tissue from patients with rheumatoid arthritis than in osteoarthritis
13. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice
14. Cytokines in synovial fluid. II. The presence of tumour necrosis factor and interferon
15. TNF alpha and the TNF receptor superfamily: Structure-function relationship(s)
16. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent
17. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis
18. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
19. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: Implications for joint and gut-associated immunopathologies
20. Infliximab and methotrexate in the treatment of rheumatoid arthritis
21. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis
22. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
23. A cytotoxicity assay for tumour necrosis factor using a human rhabdomyosarcoma cell line
24. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
25. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides
26. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
27. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
28. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact
29. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor
30. An engineered human antibody to TNF (CDP571) for active Crohn's disease: A randomized double-blind placebo-controlled trial
31. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
32. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
33. Molecular cloning and expression of a receptor for human tumor necrosis factor
34. The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
35. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins
36. Effects of two anti-tumor necrosis factor-α agents in a primate model of subcutaneous abscess formation
37. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
38. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
39. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis